MedTrace Logo

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

NCT01470118 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2013-02-21

Study results available
· View outcomes & findings →

Summary

This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.

Conditions

  • Conjunctivitis, Allergic

Interventions

DRUG

alcaftadine 0.25% ophthalmic solution

One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.

DRUG

olopatadine 0.2% ophthalmic solution

One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.

DRUG

dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%

One drop of placebo instilled in each eye at Day 0 and Day 14.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470118 on ClinicalTrials.gov